The Medicinal Chemistry and Pharmaceutics Core will be headed by Dr. Patrick Sinko, the Parke- Davis Professor of Pharmaceufics and Drug Delivery in the School of Pharmacy and Associate Vice President for Research at Rutgers University. Dr. Sinko is well known for his expertise in mechanismbased pharmacokinefics and biopharmaceutics;transport and metabolism of drugs and drug analogues of natural compounds, drug targeting, bioavailability, and the oral and brain delivery of pharmaceufical macromolecules and bioconjugate delivery vehicles. Working with Ned Heindel, the Howard S. Bunn Professor of Chemistry at Lehigh University, he will directly interact with investigators in the Research and Development Projects evaluating countermeasures to sulfur mustard. Dr. Ned Heindel's expertise is in medicinal chemistry and the synthesis of small molecular weight organic compounds. Dr. Heindel holds 11 patents on candidate pharmaceuticals, one of which was transferred to ICN Corporation (an antipsoriatic) and three of which are licensed to Baxter Corporation (antivirals). He currently serves as a contractor for Azevan Pharmaceuticals, a venture capital start-up, where he directs the medicinal-organic synthesis program which has generated a series of promising novel clinical candidates which selectively block the effects of arginine vasopressin. He has a 40 year history of academic R&D in support of commercial drug development. Both Drs. Sinko and Heindel have expertise in medicinal chemistry, drug formulations and pharmaceutical drug development. The Medicinal Chemistry group will be involved in synthesis of drug leads including structural analogs needed to identify active pharmacophores and to optimize countermeasures forfurther development. Also important will be scale-up synthesis of candidate lead compounds for animal studies. The Pharmaceufics group will be primarily focused on opfimizing delivery of countermeasures to target tissues while minimizing toxicity. Their strategy will be ADME/PK tesfing of compounds generated, if results are satisfactory in vitro, they will be tested in vivo. If compounds fail, they can be reformulated using advanced drug delivery systems available in Dr. Sinko's laboratory. This assumes that failure is a result of poor deliverability- which is often the case. If countermeasures are successful in vivo, then IND-enabling studies will be performed in collaboration with the Pharmacology and Drug Development Core.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rbhs-Robert Wood Johnson Medical School
United States
Zip Code
Moretti, Alysha; Li, Qi; Chmielowski, Rebecca et al. (2018) Nanotherapeutics Containing Lithocholic Acid-Based Amphiphilic Scorpion-Like Macromolecules Reduce In Vitro Inflammation in Macrophages: Implications for Atherosclerosis. Nanomaterials (Basel) 8:
Szilagyi, John T; Fussell, Karma C; Wang, Yun et al. (2018) Quinone and nitrofurantoin redox cycling by recombinant cytochrome b5 reductase. Toxicol Appl Pharmacol 359:102-107
Joseph, Laurie B; Composto, Gabriella M; Perez, Roberto M et al. (2018) Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anti-inflammatory and anticholinergic bifunctional prodrug. Toxicol Lett 293:77-81
Chang, Yoke-Chen; Gordon, Marion K; Gerecke, Donald R (2018) Expression of Laminin 332 in Vesicant Skin Injury and Wound Repair. Clin Dermatol (Wilmington) 2:
Yang, Shaojun; Jan, Yi-Hua; Mishin, Vladimir et al. (2017) Diacetyl/l-Xylulose Reductase Mediates Chemical Redox Cycling in Lung Epithelial Cells. Chem Res Toxicol 30:1406-1418
Venosa, Alessandro; Gow, James G; Hall, LeRoy et al. (2017) Regulation of Nitrogen Mustard-Induced Lung Macrophage Activation by Valproic Acid, a Histone Deacetylase Inhibitor. Toxicol Sci 157:222-234
Francis, Mary; Sun, Richard; Cervelli, Jessica A et al. (2017) Editor's Highlight: Role of Spleen-Derived Macrophages in Ozone-Induced Lung Inflammation and Injury. Toxicol Sci 155:182-195
Chmielowski, Rebecca A; Abdelhamid, Dalia S; Faig, Jonathan J et al. (2017) Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation. Acta Biomater 57:85-94
Francis, Mary; Groves, Angela M; Sun, Richard et al. (2017) Editor's Highlight: CCR2 Regulates Inflammatory Cell Accumulation in the Lung and Tissue Injury following Ozone Exposure. Toxicol Sci 155:474-484
Malaviya, Rama; Laskin, Jeffrey D; Laskin, Debra L (2017) Anti-TNF? therapy in inflammatory lung diseases. Pharmacol Ther 180:90-98

Showing the most recent 10 out of 145 publications